Company profile: Valencia Technologies
1.1 - Company Overview
Company description
- Provider of implantable neuromodulation solutions for urge urinary incontinence, including eCoin, a coin-sized neurostimulator implanted subcutaneously in the lower leg that delivers automatic intermittent tibial nerve stimulation to reduce symptoms, and the eCoin Physician Qualification training program to certify physicians to offer eCoin therapy.
Products and services
- ECoin: A coin-sized neurostimulator implanted subcutaneously in the lower leg, delivering automatic intermittent tibial nerve stimulation to reduce symptoms of urge urinary incontinence
- Implantable Neuromodulation System Development: Engineers an implantable neuromodulation system to treat urinary incontinence using an internally functioning device for therapy delivery
- ECoin Physician Qualification training program: Certification-based training qualifying physicians to offer eCoin therapy to patients through formal credentialing requirements process.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Valencia Technologies
Sangart
HQ: United States
Website
- Description: Provider of biopharmaceutical oxygen-therapeutic agents, pursuing global scientific, clinical and commercial development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sangart company profile →
Sirius Therapeutics
HQ: United States
Website
- Description: Provider of RNAi-based therapies for cardiovascular diseases, developing siRNA therapeutics including SRSD107 targeting coagulation Factor XI (FXI) for prevention and treatment of thromboembolic disorders with potential once- or twice-yearly dosing, and SRSD101 targeting PCSK9 to lower LDL-C for dyslipidemia; leveraging proprietary technology platforms and infrastructure in the US and China.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sirius Therapeutics company profile →
Acron Genomics
HQ: United Kingdom
Website
- Description: Provider of novel biotechnology platform development and commercialization in the life sciences, and of the introduction and development of promising new pharmaceutical compounds. U.S. publicly traded (OTC Markets/AGNM).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Acron Genomics company profile →
Cardio Polymers
HQ: United States
Website
- Description: Provider of biocompatible polymer implant therapies and implantable devices to treat chronic heart failure, mitral valve regurgitation, and postoperative atrial fibrillation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cardio Polymers company profile →
Respicardia
HQ: United States
Website
- Description: Provider of implantable therapies to improve respiratory rhythm management and cardiovascular health, including the FDA-approved remedē System for adults with moderate to severe Central Sleep Apnea (CSA) to restore normal breathing during sleep, and the remedē Patient Pathway offering resources for screening, selection, implant, optimization, and follow-up.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Respicardia company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Valencia Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Valencia Technologies
2.2 - Growth funds investing in similar companies to Valencia Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Valencia Technologies
4.2 - Public trading comparable groups for Valencia Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →